Organovo (ONVO) Reports In-Line Q4 EPS, Miss on Revenues
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
Organovo Reports Fiscal Fourth-Quarter and Full-Year 2018 Results; Company Announces Key Goals for Fiscal-Year 2019
May 31, 2018 4:05 PM EDT- Lead Investigational New Drug (IND) program for Alpha-1-antitrypsin deficiency (A1AT) received FDAs orphan drug designation and is on track for commencing IND-enabling studies in fiscal 2019
- Second IND-track program in orphan liver disease expected to be nominated in fiscal 2019
SAN DIEGO, May 31, 2018 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (NASDAQ: ONVO) (Organovo), Â a biotechnology company pioneering the development of 3D bioprinted tissues aimed at treating a range of serious adult and pediatric liver diseases, today reported its fiscal fourth-quarter and full-year 2018 financial results and announced its key... More
